Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,601–2,700 of 3,116
Al-Nusair, M., Maini, A., Khurana, S., & Al‐Nusair, J. (2026) · medRxiv · doi:10.64898/2026.09.21.26363576
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetes aktuell · doi:10.1055/a-2539-0910
Waqas, S. A., Ibrahim, M., Ahmed, M., Waqas, M., Aamir, J., Fudim, M., Musani, M. H., Fonarow, G. C., & Greene, S. J. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01969-6 · Cited by 1
“…ejection fraction; FLOW [ 6 ] and AMPLITUDE-O [ 4 ] focused on individuals with type 2 diabetes mel - litus and chronic kidney disease; SELECT [ 2 ] enrolled non-diabetic participants; whereas LEADER [ 1 ], SUS - TAIN-6 [7] and HARMONY [8] included patients with established type 2 diabetes…”
Leitliniengerechte Therapie der chronischen Nierenerkrankung
Weiland, L. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5135-y
Shah, S., Abusafia, M., Sheashaa, H., Jadam, S., Ospina, S., Kaelber, D., Keen, S. K., & Desai, M. Y. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102955
Rivero-Moreno, Y., Estrada, A., Hindosh, N., Zamata-Ovalle, D., Choi, J., Moran-Atkin, E., & Camacho, D. R. (2025) · Research Square · doi:10.21203/rs.3.rs-6033446/v1
Milluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02189-x
Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial
Heerspink, H. J. L., Soler, M. J., Beernink, J. M., Jongs, N., Guldris, S. C., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Apperloo, E. M., Waanders, F., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001051 · Cited by 3
Huang, H., Liu, J., Lu, X., Tan, N., & Liu, Y. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf065 · Cited by 1
Body mass index (BMI) and clinical outcomes after PCI
Anwari, E., Abdelwahed, Y. S., & Landmesser, U. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag075
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“Semaglutide reduced the risk of death from cardiovascular causes, nonfatal myocardial infarction, or non-fatal strokes by 20% compared to placebo [45], with a more pronounced risk reduction (26”
Semaglutide reduces proteomic organ-specific biological age across randomized clinical trialsPreprint
Dermit, M., Colhoun, H. M., Goeminne, L. J. E., Ryan, D. H., Adelborg, K., Belmont-Rausch, D. M., Kolnes, K. J., Knop, F. K., Voisin, S. A. C., Gladyshev, V. N., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11082091/v1
Self-citationCorrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
How to reduce side effects of GLP-1 based obesity medications
Alhazmi, A., & le Roux, C. W. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.02.001
Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review
Bihelek, N., Burke, S., & Barry, A. R. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag121
Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
Zeitler, E. M., Klein, K. R., Lingvay, I., Pick, A., & Billings, L. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70781 · Cited by 2
Self-citationVera-Ponce, V. J. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100308
“Semaglutide 2.4 mg and tirzepatide have shown substantial weight reductions in randomized trials, and the SELECT trial showed a reduction in major cardiovascular events with semaglutide in people with overweight or obesity and established cardiovascular disease, without diabetes [7 – 12].”
InfluentialCardiovascular Outcomes in Low-Risk Non-Diabetic Patients Treated with SemaglutidePreprint
Komatsoulis, G. A., Shvets, A. A., Flamholz, Z., Khera, R., Pindak, S., Tann, N., Wolinsky, J., Hudzik, A., Stanford, R. H., Patel, M. R., et al. (2025) · medRxiv · doi:10.1101/2025.05.20.25327768
Dose-Response Assessment of Semaglutide: High-Dose-Induced Hepatotoxicity in Male Albino Rats
Sakr, F. N., & Lateff, N. I. (2026) · AMPLITUDO Journal of Science & Technology Innovation · doi:10.56566/amplitudo.v5i2.616
GLP-1 agonists and cardiovascular endpoints in obesity without diabetes
Verlaan, J. P. L. (2025) · Geneesmiddelenbulletin · doi:10.35351/gebu.nl.2025.2.6
El‐Kassas, M., Awad, A., AlNaamani, K. M., Alswat, K., & Elzouki, A.-N. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.57
Awadalla, L., Iskander, S., Chu, C., & Tadrous, M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0248 · Cited by 1
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Dardari, D. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261478400
“11 For patients with IBD who meet metabolic indications, these benefits are intrinsically valuable regardless of any intestinal effect.”
Khela, H. S., Kishan, A., Manriquez, A. H., Kirby, L., Chisango, Z. M., Carayannopoulos, N. L., Singh, M., Cottrill, E. J., Avedian, R. S., Kleck, C. J., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000051 · Cited by 1
Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future
Everett, B. M., Pagidipati, N. J., & Wang, C. C. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00011-2
Pavshintsev, V. V., Erbaeva, A. Z., Vatlin, A. A., & Mitkin, N. A. (2026) · Biomedicines · doi:10.3390/biomedicines14091987
“In the SELECT trial, semaglutide improved cardiovascular outcomes, including major adverse cardiovascular events, in overweight/obese patients without diabetes [3].”
Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related MorbiditiesPreprint
Kim, M., Chen, Q.-L., Sui, Y., Yang, X., Wang, S.-Q., Weng, L.-C., Cho, S. M. J., Koyama, S., Zhu, X., Yu, K., et al. (2024) · medRxiv · doi:10.1101/2024.11.01.24316620 · Cited by 3
Semaglutide After Catheter Ablation: A New Chapter in Atrial Fibrillation Care?
Middeldorp, M. E., & Shahmohamadi, E. (2025) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014508
Peng, Z., Liang, X., Su, L., You, Z., Zhu, L., Yang, Y., Wang, Y., Liu, D., & Liang, M. (2026) · American Journal of Nephrology · doi:10.1159/000552163
Konservative Therapie des chronischen Koronarsyndroms
Asmussen, A., & Hilgendorf, I. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2442-7841 · Cited by 1
Effects of semaglutide on subclinical cardiovascular health in people with HIV
Daher, J., Koberssy, Z., Moussallem, N., Wu, Q., Sattar, A., Fletcher, A. A., McComsey, C. M., Funderburg, N., Ailstock, K., & Eckard, A. R. (2026) · AIDS · doi:10.1097/qad.0000000000004624 · Cited by 1
Geraci, C., Rocca, F. L., Petrina, S. M., Buonauro, A., Morello, V., Paternò, V., Santoro, C., Geraci, G., & Esposito, R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155909
Keskinler, M. V., Özgül, M., Koç, D., Kanlıçay, I., & Oğuz, A. (2026) · doi:10.2196/preprints.113096
Simioni, L., Bennar, W., Beretta, G. S., Pittet, T., Cioffi, G. M., Jelisejevas, J. J., Wenaweser, P., Meier, P., Puricel, S., Togni, M., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13060251
“Similarly, ongoing outcome trials evaluating newer incretin-based therapies, such as tirzepatide, are expected to further clarify the relationship between adiposity reduction and cardiovascular risk [75–77].”
Issaka, Y., Abdul-Kareem, H., Meyahnwi, D., Ntow, M. A., & Hahn, S. S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.055 · Cited by 1
Biswas, S., Wahba, A., Srivastava, Y., Kumar, K., Chintagumpala, V., & Said, S. M. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001393
Lanier, A., Lutolli, F., & Belkin, M. N. (2025) · ESC Heart Failure · doi:10.1002/ehf2.70015
Kapoor, N., Shaikh, S. S., Bhattacharya, S., Kalra, S., Das, S., KOTA, S., Khandelwal, V., Naskar, A., Dange, A., Sorate, S., et al. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00290-8
“These trials consistently showed significant reductions in HbA1c, body weight, and major adverse cardiovascular events (MACE) in patients with T2DM and obesity [2–4].”
Shirmohamadi, E., Ghasemloo, N., Ebrahimi, N., Mohammadzadeh, N., Ehtemami, A., Babaei, M., & Fardoost, S. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70311
Sorić, T., Sarić, A., Ivanišin, A., Lovrić, M., Milić, M., Matovinović, M., & Sarić, M. M. (2026) · Nutrients · doi:10.3390/nu18172757 · Cited by 2
“Nutritional outcomes were not predefined endpoints in most pivotal randomized clinical trials evaluating semaglutide, liraglutide, or tirzepatide, and systematic biochemical assessment of micronutrient status has rarely been incorporated into study protocols [1,2,4,48–51].”
Muir, K. C., Stone, C. R., & Sellke, F. W. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm46451
Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications
Mohan, V., Kalra, S., Ahluwalia, A. I., Gangopadhyay, K. K., Bhattacharyya, A., Saboo, B., Kesavadev, J., Ramakrishnan, S., Lakhani, O., Nagendra, L., et al. (2026) · Cureus · doi:10.7759/cureus.114959
Seweryn, M., Bała, M. M., Juszczyk, G., Nowak, F., & Jankowska, E. P. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1811509
“…enabling the most seriously affected patients to benefit from reimbursed modern pharmacotherapy for obesity, which, as the SELECT study has shown for semaglutide, can significantly reduce the risk of cardiovascular events and mortality in patients with diagnosed cardiovascular disease (48).”
Impact of heart failure on postoperative outcomes in bariatric surgery
LaPenna, K. B., Corpodean, F., Castanon, C., Kachmar, M., Schauer, P. R., & Albaugh, V. L. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.10.009
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
A Sex-specific Mendelian Randomization-Phenome-Wide Association Study of Body Mass IndexPreprint
Jiesisibieke, Z. L., Chan, I. I., Ng, J. C. M., & Schooling, C. M. (2024) · eLife · doi:10.7554/elife.102573.1
Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern
Koufakis, T., Tentolouris, A., Karakasis, P., Popovic, D. S., & Patoulias, D. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03804-z
Pillai, A. A., Godin, S., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001310 · Cited by 1
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.70003
A sex-specific Mendelian randomization-phenome-wide association study of body mass indexPreprint
Jiesisibieke, Z. L., Chan, I. I., Ng, J. C. M., & Schooling, C. M. (2024) · eLife · doi:10.7554/elife.102573 · Cited by 1
Quinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
“…enhanced lipolytic activity and direct por - tal circulation to the liver, contributing to hepatic insulin resistance and dyslipidemia characteristic of the metabolic syndrome [126 ] (Table 3). reduction of 15.2%, with cardiovascular benefits cor - relating with the degree of weight loss [55, 139].”
InfluentialKomatsoulis, G. A., Shvets, A. A., Flamholz, Z., Khera, R., Pindak, S., Tann, N., Wolinsky, J., Hudzik, A., Stanford, R. H., Patel, M. R., et al. (2025) · Next research. · doi:10.1016/j.nexres.2025.100587 · Cited by 3
Dutta, N., Tessier, K., Langer, J., Harindhanavudhi, T., Sibley, S. D., Billington, C. J., Vock, D. M., Wise, E. S., Bomberg, E. M., & Bramante, C. T. (2025) · Cureus · doi:10.7759/cureus.94070 · Cited by 1
Furtado, R. H. D. M. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250251
Ruseva, A., Michalak, W., Bassan, M., Du, E. X., Fabricatore, A. N., Hartaigh, B. Ó., Man, T., Ramasubramanian, R., Shen, P., Song, J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70746 · Cited by 1
“This approval was based on semaglutide 2.4 mg's significant cardiovascular benefit demonstrated in the multinational, placebo-controlled SELECT trial of 17 604 adults with overweight or obesity and established cardiovascular disease, but without diabetes [19].”
InfluentialTareen, M. K. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133211
Picinin, V. D., Balbinott, L. T., Spolaor, A., & Barachini, A. P. (2025) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i2.2025.1731
Algazzar, A. S. (2026) · Saudi Journal of Internal Medicine · doi:10.4103/sjim.sjim_12_26
Lum, J., Jordan, A., Knigh, P., & Hisamoto, K. (2026) · medRxiv · doi:10.64898/2026.06.02.26354773
Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA
Blair, C. V., Huck, D. M., Besser, S. A., Cardoso, R. N., Shiyovich, A., Berman, A. N., Biery, D. W., Weber, B., Petranović, M., Nasir, K., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101995
Self-citationJiang, X., Hirschmüller, N., Taylor, H. J., Dalakoti, M., Needham, E. J., Kelemen, M., Jiang, T., Ritchie, S. C., Vidal‐Puig, A., Butterworth, A. S., et al. (2026) · medRxiv · doi:10.64898/2026.08.24.26361276
Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization
Bergeron, N. P., Egbe, A. C., Miranda, W. R., Gulati, R., Demmer, R. T., Sundaram, V., Borlaug, B. A., & Reddy, Y. N. V. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102899
Attar, J. A., von Martial, S., Troost, K., Neumeister, T., Ehrchen, J. M., Steinbrink, K., Muke, J., & Tsianakas, A. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15585_g
What’s VAT All About—The Clue Is in the Genetics
Day, S. M. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0092
Wang, F., Shen, C., Guo, W., Wang, J., Xie, J., Shen, G., & Lin, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s601248
“24,25 Direct DPN-specific evidence for semaglutide remains limited, and further dedicated trials are needed.”
Understanding the Impact of Systemic Medications on Diabetic Retinal Disease
Silva, P. S. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.03.006
Maksimov, M. L., Sidorova, A. D., Kizlik, S. V., & Kizlik, V. A. (2026) · doi:10.33920/med-13-2603-01
Oettinger, V., Mühlen, C. V. Z., Kaier, K., Wolf, D., Rilinger, J., Maier, A., Jäckel, M., Westermann, D., Hilgendorf, I., & Bockelmann, D. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02735-z
Beyond the Skinfolds: Diagnostic and Therapeutic Hope for the Obese and Formerly Obese
Miller, D. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.014
Pineño, O. (2026) · Food Quality and Preference · doi:10.1016/j.foodqual.2026.106111
Obesity and hypertension new insights in management
Catalfamo, V. J., Koos, A., Tutor, A. W., & Lavie, C. J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001261
Access to Anti-Obesity GLP-1s for Medicare-Aged AdultsPreprint
Rodriguez, P. J., Zhang, V., Gratzl, S., Cartwright, B. M. G., Do, D., Stucky, N. L., & Emanuel, E. (2024) · medRxiv · doi:10.1101/2024.03.26.24304923
AlTaweel, M., Husain, M. A., AlSubaiee, M., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2692167
“Semaglutide, a once-weekly GLP-1 RA, produces more substantial weight loss through hypothalamic appetite suppression and delayed gastric emptying, achieving up to a 15% reduction in body weight in the SELECT trial 8,9 .”
Type 2 diabetes does not inevitably shorten life expectancy
Du, H. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100029
“Recent years have witnessed major advances in obesity and diabetes pharmacotherapy, such as semaglutide and tirzepatide [8,9].”
Nasir, L., Jalal, L., Siddiqa, A., Nasir, A., Farooqui, M., & Siddiqui, A. H. (2025) · European Journal of Therapeutics · doi:10.58600/eurjther2817
The Fairness Dividend™: How Artificial Intelligence Gives Humanity One Last Chance to Get It RightPreprint
Picken, T. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6822282
Puchnerová, V., Jenšovský, M., Ošťádal, P., & Bonaventura, J. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.039
Cost per event avoided: adopt or avoid?
Pitsillidou, O., Petrou, P., Petrou, C. P., et al. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2638716
The Cardio-Renal-Hepatic Axis in MASLD. Role of BDNF, NGF, and Metabolic Cross-Talk
Taylor, L. C., Adenawoola, M. I., Wingfield, C. B., Nadolski, M. K., & Stec, D. E. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01388-1
“On the cardiovascular side, GLP-1 RAs reduce major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, while lowering blood pressure, reducing EAT, and improving endothelial function and lipid profiles [ 73].”
Ndubisi, S., & Lio, P. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.005 · Cited by 1
DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic Fabry disease
Riccio, E., Cuomo, A., Capuano, I., Spinelli, L., Iaccarino, G., Marco, O. D., & Pisani, A. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag115
Ahad, A., Hullon, D., Akhavan, M., & Oskouyan, Z. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10839-8 · Cited by 1
“…metabolic reprogramming, GLP-1-based cardiovascular and inflammatory modulation, and exercise training to restore neuromuscular and cardiorespiratory integration are positioned to produce the functional outcomes that individual pathway modulation has not reliably achieved [42, 59–61].”
Bruenderman, E. H., Eisa, M., Pearlman, M. Y., & Mundi, M. S. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00537-4
“…hypertension, hyperlipidemia, cardiovascular disease, obstructive sleep apnea, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatohepatitis in selected populations, leading to expanding regulatory approvals and broader clinical use [25–27, 29, 31–33].”
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
Midlife weight gain: challenges and solutions
Hung, S., & Adams, K. E. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001093 · Cited by 1
Palshetkar, N., Pai, H. D., Patel, M. A., Patki, A. S., Tandulwadkar, S. R., Purandare, A., Tambe, P., Palshetkar, R., Pai, M. V., Banerjee, D., et al. (2024) · Indian Journal of Obstetrics and Gynecology Research · doi:10.18231/j.ijogr.2024.063 · Cited by 1
Butensky, S. D., Hamid, S. A., Graetz, E., Ying, L., Schwartz, J. S., Schneider, E. B., Ghiassi, S., & Gibbs, K. E. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08645-x · Cited by 1
A potent novel small molecule GLP-1R agonist identified by rational design and CADD
Chen, J., Yao, Y., & Li, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118578 · Cited by 1
Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
Renehan, A. G., & Pollak, M. (2026) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-26-0018 · Cited by 2
GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
Boeckhaus, J., Sayer, J. A., & Mabillard, H. R. (2026) · Clinical Science · doi:10.1042/cs20261312
Ritsinger, V., Fagerström, J., Nero, H., Cars, T., Svensson, M. K., & Norhammar, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70899
The Year in Review in Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.001
Pozzi, E., Birolini, G., Luca, S. D., & Salonia, A. (2025) · International Journal of Impotence Research · doi:10.1038/s41443-025-01126-2 · Cited by 1
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Abdalla, S. A. M., Gharbawi, L., Elshaikh, N., Omer, E. O. E., Osman, A. F. M., Ali, A. S. H., Mohamed, T. M. Y., & Alhajri, A. H. M. (2026) · Cureus · doi:10.7759/cureus.114454
“Semaglutide has a definitive randomised cardiovascular outcome trial in the obesity population: SELECT demonstrated a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes [8].”
Farmakovijilansın Önemi: GLP-1 Reseptör Agonistlerinin Etkinlik ve Güvenliliği
Kayan, G. T., & Karataş, Y. (2026) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1976223
Reprise de poids après chirurgie bariatrique : intérêt des analogues GLP-1 et GIP
Bacchetta, C. (2025) · Pratiques en nutrition · doi:10.1016/j.pranut.2025.03.011
Serretti, A. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000614
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
